Sluchay uspeshnoy terapii nilotinibom (Tasignoy) patsientki s Ph-pozitivnymkhronicheskim mieloleykozom v khronicheskoy faze s rezistentnost'yu k interferonui Gliveku
Всвязи с выдающимися результатами, достигнутыми при применении ингибитора Bcr-Abl-тирозинкиназы иматиниба (Гливек®, Новартис Фарма), данный препарат стал стандартом терапии больных хроническим миелолейкозом (ХМЛ) на всех стадиях болезни. Применение Гливека в качестве препарата первой линии терапии в...
Main Authors: | N A Afanas'eva, G A Gusarova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2008-09-01
|
Series: | Современная онкология |
Subjects: | |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26735 |
Similar Items
-
Nilotinib - new step of success in CML therapy
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS
by: R. I. Yagudina, et al.
Published: (2015-03-01) -
International CML forum
by: A. G. Turkina
Published: (2022-11-01) -
Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis
by: I. N. Mikhaylova, et al.
Published: (2021-01-01) -
CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES
by: G. Sh. Safuanova, et al.
Published: (2019-05-01)